MorphoSys and GlaxoSmithKline Partner in Antibody Pact - - BioPharm International

ADVERTISEMENT

MorphoSys and GlaxoSmithKline Partner in Antibody Pact


MorphoSys has formed a global agreement with GlaxoSmithKline (GSK) to develop and commercialize MOR103, MorphoSys's proprietary HuCAL-derived antibody for treating mild to moderate rheumatoid arthritis. Under the agreement, GSK assumes responsibility for all subsequent development and commercialization of MOR103. MorphoSys receives an immediate upfront payment of EUR 22.5 million ($29.4 million) and up to EUR 423 million ($552 million), in addition to tiered, double-digit royalties on net sales, based on achieving certain developmental, regulatory, commercial and sales-based milestones.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines

Click here